Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet
U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 400 points on Tuesday.
Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Tuesday.
The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint
Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
Protagonist Therapeutics Announces Topline Data From Phase 2 IDEAL Study Of PN-943 In Ulcerative Colitis; Says 450mg Bid Dose Of Pn-943 Did Not Meet Prespecified Primary Endpoint In Study
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong